Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33) | Apply Online

Opportunity Summary:

The National Institutes of Health (NIH) funding opportunity titled "Phased Innovation Research in Cancer Prognosis and Prediction (R21/R33)" (Funding Opportunity Number PA 06 434) supports research aimed at improving how clinicians forecast cancer outcomes and predict how patients will respond to specific therapies. The central goal is to accelerate the development and early clinical evaluation of new prognostic or predictive strategies, such as novel assays, biomarkers, test systems, or analytical approaches, that can meaningfully guide treatment choices and patient management. By emphasizing tools that strengthen clinical decision making, the FOA is geared toward projects that move beyond basic discovery and into practical, testable methods that can be piloted in settings relevant to patient care.

This program uses a phased grant structure that links two stages of work under one application: an initial R21 phase followed by a second R33 phase. The R21 portion is meant for early technical development and proof-of-principle work. In practice, that means investigators should use the first phase to demonstrate that their proposed strategy is technically feasible and ready for more rigorous application. A key expectation is that the R21 generates concrete data showing the assay or test system performs analytically as intended, ideally using specimens and conditions comparable to what will be used later. The emphasis is on reducing risk before moving into the more applied evaluation stage, so the R21 should directly support the design and readiness of the second phase rather than functioning as an open-ended exploratory study.

The R33 phase is intended to take a strategy that has cleared the technical feasibility bar and push it into further development, application, and evaluation of clinical utility. Here the project should be structured to answer whether using the strategy actually helps a defined group of cancer patients, for example by improving treatment selection, anticipating response or resistance, refining prognosis, or otherwise producing a clinically meaningful benefit. The R33 is therefore oriented toward real-world usefulness rather than purely technical performance, and applicants are expected to define the patient population and clinical context clearly enough that the value of the strategy can be evaluated in a credible, measurable way.

From an administrative standpoint, this is a discretionary NIH grant in the education and health activity area, listed under CFDA 93.394 (Cancer Detection and Diagnosis Research). The opportunity anticipated about 10 awards, with an award ceiling listed as $200,000. The announcement was originally posted May 23, 2006, and it used multiple receipt dates rather than a single deadline, with the current closing date shown as May 7, 2009 and an archive date of June 7, 2009. Cost sharing or matching was not required, which lowers the barrier for many organizations that may not have non-federal funds available to contribute.

Eligibility is broad and includes many types of applicant organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), state and local governments (including county and city/township governments), independent school districts, special district governments, public housing authorities and Indian housing authorities, and Native American tribal governments as well as other tribal organizations. For-profit organizations other than small businesses are also eligible, and the FOA explicitly notes that foreign institutions may apply, eligible federal agencies may apply, and faith-based or community-based organizations may apply as well. Applicants are allowed to submit more than one application as long as each proposed project is scientifically distinct, which can be useful for groups developing multiple independent platforms or pursuing different cancer use-cases.

Overall, the opportunity is designed for teams that have a promising new approach to cancer prognosis or treatment-response prediction and can lay out a credible pathway from technical validation to early demonstration of clinical utility. The two-phase R21/R33 structure is meant to encourage innovation while still requiring a disciplined transition from feasibility data to a more applied, patient-relevant evaluation. For full details, NIH directed applicants to the official announcement page (http://grants.nih.gov/grants/guide/pa-files/PA-06-434.html) and provided NIH Office of Extramural Research contact support for access or linking issues (FBOWebmaster@OD.NIH.GOV).

Browse more business programs for Innovation Research Organizations

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: Phase II Developmental Research in Cancer Prognosis and Prediction (R33)

Previous opportunity: Exploratory/Developmental Bioengineering Research Grants(EBRG) R21

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 06 434

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 06 434) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 434", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.